160 related articles for article (PubMed ID: 2013808)
1. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
[TBL] [Abstract][Full Text] [Related]
2. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET for predicting the prognosis of malignant lymphoma.
Okada J; Oonishi H; Yoshikawa K; Itami J; Uno K; Imaseki K; Arimizu N
Ann Nucl Med; 1994 Aug; 8(3):187-91. PubMed ID: 7811561
[TBL] [Abstract][Full Text] [Related]
4. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
[TBL] [Abstract][Full Text] [Related]
5. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
7. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.
Karam M; Novak L; Cyriac J; Ali A; Nazeer T; Nugent F
Cancer; 2006 Jul; 107(1):175-83. PubMed ID: 16721817
[TBL] [Abstract][Full Text] [Related]
8. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study.
Leskinen-Kallio S; Ruotsalainen U; Någren K; Teräs M; Joensuu H
J Nucl Med; 1991 Jun; 32(6):1211-8. PubMed ID: 2045935
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.
Okada J; Yoshikawa K; Itami M; Imaseki K; Uno K; Itami J; Kuyama J; Mikata A; Arimizu N
J Nucl Med; 1992 Mar; 33(3):325-9. PubMed ID: 1740697
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
[TBL] [Abstract][Full Text] [Related]
12. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.
Lapela M; Leskinen S; Minn HR; Lindholm P; Klemi PJ; Söderström KO; Bergman J; Haaparanta M; Ruotsalainen U; Solin O; Joensuu H
Blood; 1995 Nov; 86(9):3522-7. PubMed ID: 7579459
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of FDG-PET in malignant lymphoma.
Becherer A; Jaeger U; Szabo M; Kletter K
Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Lorenz WJ; Maier-Borst W; van Kaick G
Eur J Nucl Med; 1995 May; 22(5):434-42. PubMed ID: 7641752
[TBL] [Abstract][Full Text] [Related]
15. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy.
Hoekstra OS; Ossenkoppele GJ; Golding R; van Lingen A; Visser GW; Teule GJ; Huijgens PC
J Nucl Med; 1993 Oct; 34(10):1706-10. PubMed ID: 8410287
[TBL] [Abstract][Full Text] [Related]
16. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma.
Paul R
J Nucl Med; 1987 Mar; 28(3):288-92. PubMed ID: 3469332
[TBL] [Abstract][Full Text] [Related]
18. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman JS; Francis IR; Kaminski MS; Wahl RL
Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography.
Bares R; Galonska P; Dempke W; Handt S; Büll U; Osieka R
Horm Metab Res Suppl; 1993; 27():56-8. PubMed ID: 8330873
[TBL] [Abstract][Full Text] [Related]
20. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Eur J Haematol; 2015 Jul; 95(1):83-9. PubMed ID: 25537478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
